TyRx Pharma, Inc.: Series A $25M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Drug:Device Combo

TyRx Pharma (Monmouth Junction, NJ) a commercialization-stage developer of implantable drug-device combination products closed a $25M Series A financing. Participants include Clarus Ventures and Pappas Ventures.

Vaccinex, Inc.: Series B $25M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Inflammation, X - Oncology

Vaccinex (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Affomix, Corp.: Series A $7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Antibody, X - Microarray

Affomic (New Haven, CT) a development stage biotechnology company designing antibody microarrays closed a $7M Series A financing. Participants include Connecticut Innovations, Elm Street Ventures, and Four Seasons Ventures.

Alverix, Inc.: Series A $7.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diagnostic

Alverix (Wayne, Pa) developer of point-of-care diagnostics devices closed a $7.7M Series A financing. Participants include New Venture Partners and Safeguard Scientifics.

Knopp Neurosciences, Inc.: Series B $10M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - ALS, X - Neurology

Knopp Neurosciences (Pittsburgh, PA) a drug discovery and development company focused on neurological disorders with a lead compound for amyotrophic lateral sclerosis closed a $10M Series B financing. Participants include Saturn Partners, Kramer Capital Partners and LaunchCyte.

Follica, Inc.: Series A $5.5M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Hair Loss

Follica (Boston, MA) is developing novel therapies for the treatment of androgenetic alopecia and other disorders associated with the hair follicle has, closed a $5.5M Series A financing. Participants include Interwest Partners and PureTech Ventures.

Escoublac, Inc.: Series A $6.7M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

Primera Biosystems, Inc.: Series B $21M

Posted in I - Series B, Q - 1Q08, R - NORTH EAST, X - Device (Diagnostic)

Primera Biosystems (Mansfield, MA) developer of novel assays and instrument systems to enable simultaneous quantitative measurement of multiples genes in a single assay closed a $21M Series B financing. Participants include Abingworth, Interwest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

Gelesis, Inc.: Series A $16.0M

Posted in I - Series A, Q - 1Q08, R - NORTH EAST, X - GI, X - Obesity

Gelsis (Boston, MA) is developing a breakthrough treatment for obesity and other gastrointestinal disorders has closed a $16M Series A. Participants include OrbiMed, Queensland BioCapital Funds, PureTech Ventures, Lansing Brown Investments and the Cape Family Fund.

AgaMatrix, Inc.: Series C $23.7M

Posted in I - Series C, Q - 1Q08, R - NORTH EAST, X - Device (Diabetes)

AgaMatrix (Salem, NH) maker of blood glucose monitoring systems that provide results to help users better manage their diabetes closed a $23.7M Series C financing. Participants include Ferrer Freeman & Co.

« Previous Entries

to top of page...